Functional Genetics, Inc. - Using Innovative Science to Develop New Therapeutics for Infectious Diseases

The FGI-111 program is developing fully human antibodies for the treatment or prevention of sexually transmitted diseases.

The program targets a host molecule, Robo1, which is "hijacked" in cells that have been infected with a broad spectrum of different sexually-transmitted viruses including all forms of HIV-1 and HIV-2, regardless of geographic origin, tropisms or established drug resistance.  The target is also applicable to a broad spectrum of other sexually-transmitted and respiratory pathogens.

FGI's core discovery engine, Random Homozygous Gene Perurbation (RHGP), identified Robo1 as a target for a broad spectrum medicine to treat or prevent infection by sexually-transmitted viruses.